Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Thyroid Gland Medullary Carcinoma
Drug:
Cabometyx (cabozantinib tablet)
(
Multi-tyrosine kinase inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Medullary Thyroid Carcinoma...Vandetanib and cabozantinib, oral kinase inhibitors, are recommended for the treatment of medullary carcinoma in patients with unresectable locally advanced or metastatic disease…
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.